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Long-term predictors of survival in essential mixed cryoglobulinemic
glomerulonephritis. We report the clinical outcome of 105 essential mixed
ciyoglobulinemia (EMC) patients with renal involvement collected
throughout 25 years in three renal Units of Milan. The median follow-up
was 72 months since renal biopsy and 131 months since the clinical onset
of EMC. Patient survival was 49% at 10 years after renal biopsy. Forty-two
patients died primarily from cardiovascular and liver disease or infection,
whereas 15 patients developed chronic renal failure. Two patients had a
complete remission of the disease while 15 had a remission only of renal
signs. Thirty-one patients are alive with persistent renal and extrarenal
manifestations. Anti-HCV antibodies were retrospectively detected in 34
patients and were present in 85% of them. This variable was not included
in the statistical evaluation. At multivariate analysis, age older than 50
years, purpura, splenomegaly, cryocrit levels higher than 10%, C3 plasma
levels lower than 54 mgldl, and serum creatinine higher than 1.5 mg/dl
were independent risk factors for death or dialysis. In conclusion, several
factors may influence the outcome of patients with EMC nephritis.
Markers of disease activity and an impaired renal function can herald a
bad prognosis. It should be stressed, however, that only a minority of
patients eventually develop renal failure, probably because in the most
severe cases patients die earlier.
After the initial description by Meltzer and Franklin [1], several
papers have reviewed the clinical features of the so-called essen-
tial mixed cryoglobulinemia (EMC) [2—4], a disease caused by the
formation of high molecular weight aggregates of two immuno-
globulins: usually a polyclonal IgG and a monoclonal 1gM with
antiglobulin activity. The etiology of EMC is unknown. Recently it
has been shown that most of patients with EMC are carriers of
hepatitis C virus which could represent the triggering agent
leading to the abnormal immune response [5—7].
Clinically, EMC is characterized by the triad of purpura,
arthralgias and weakness. The clinical course of patients with
cryoglobulinemia is variable: some patients have an indolent
course while others develop vasculitic lesions in the lung, nervous
system and in the bowel. Of particular importance is the devel-
opment of a renal disease, since nephritis represents a hallmark of
a severe prognosis [8]. However, differences in the severity of
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renal involvement, in the duration of follow-up and in the type of
treatment, as well as the small number of patients enrolled in
different series, have not permitted a definition of the long-term
prognosis and the prognostic predictors of patients with EMC
nephritis.
In this paper we report the long-term outcome of 105 patients
with EMC nephritis who were followed by three renal units
working in Milan.
Methods
The medical histories of all patients with EMC who were
hospitalized at the Nephrology Divisions of Ospedale Maggiore,
Ospedale S. Carlo and Ospedale Ca' Granda of Milan, between
1966 and 1990 were reviewed. Patients were eligible for the study
if they had a diagnosis of EMC nephritis made according to the
following criteria: (a) circulating cryoglobulins, (b) rheumatoid
factor activity in their serum, (c) history of recurrent episodes of
purpura, (d) urinary protein excretion greater than 0.5 g per day
and/or urinary sediment showing erythrocytes and casts, (e) renal
biopsy showing a pattern of cryoglobulinemic nephritis, (f) a
minimum follow-up of one year after diagnosis unless the patient
died or progressed to renal failure. Out of 140 patients given a
diagnosis of EMC, 35 were excluded because of a too short
follow-up or lack of renal biopsy; 105 patients fulfilled the above
inclusion criteria and were selected for this study. The ciyoglob-
ulin typing showed: type I cryoglobulinemia in 4 patients, type II
in 60, type III in 18. In 23 patients the light chains of both M and
G immunoglobulins were undetermined.
Proteinuria was defined as an urinary protein excretion greater
than 0.5 g per day. Microscopic hematuria was defined as more
than 1 plus detected with multistix. Nephritic syndrome was
defined as a combination of microscopic hematuria, proteinuria,
hypertension and a rapid increase in plasma creatinine over 1.5
mg/dl. Nephrotic syndrome was defined as an urinary protein
excretion greater than 3.5 g per day. Chronic renal failure was
defined as a plasma creatinine over 4.0 mg/dl for at least six
consecutive months.
Renal biopsies were reviewed and the diagnosis of EMC was
based upon the already established histological criteria [9, 10].
The severity of the pathological involvement was scored by means
of ordinal scale. A score of 0 (absent), 1 (mild), 2 (moderate), and
3 (severe) was assigned to each of the following morphological
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features: intracapillary proliferation, epithelial proliferation, leu-
kocyte and monocyte exudation, subendothelial deposits, intralu-
minal thrombi, glomeruloscierosis, interstitial inflammation, tu-
bular atrophy and/or interstitial fibrosis, fibrinoid necrosis of
arterial wall, arterial intimal fibrosis and sclerosis. The percentage
of hyaline glomeruli was graded as 0 (absent), 1 (10%), 2
(>11%). An activity index was calculated on the basis of the sum
of nine items, that is, intracapillary proliferation, epithelial pro-
liferation, subendothelial deposits, leukocyte and monocyte exu-
dation, intraluminal thrombi, interstitial inflammation and fibrin-
oid necrosis of the arterial wall. A chronicity index was calculated
by summing the scores of four items: percentage of scierosed
glomeruli, glomerular sclerosis, tubular atrophy and/or interstitial
fibrosis, arterial intimal fibrosis and sclerosis. The renal biopsies
were also processed by immunofluorescence. The intensity of
immunoreactants (IgA, 1gM, IgG, Clq, C3 and C4) were graded
as 0, 1, 2, 3.
After November 1989, an ELISA method was available to
check the presence of anti-HCV antibodies in patients' sera. For
this purpose, the following materials were utilized: 8 fresh serum
samples, 15 serum samples frozen at —80°C, purified cryoprecip-
itate components stored at —80°C (33 samples). Thirty-four
patients were tested. Frozen serum samples and purified cryopre-
cipitate components were collected since 1980. The detection of
anti-HCV antibodies was simultaneously evaluated by second
generation ELISA (Ortho Diagnostic System, Raritan, NJ, USA)
and by recombinant immunoblot assay (RIBA 2, Ortho).
Purified cryoglobulin fractions were obtained by eluting the
cryoprecipitate dissolved in 0.1 M acetic acid through a Sephadex
G-200 column (Pharmacia Fine Chemicals, Upsala, Sweden) with
acetic acid 0.1 M solution, pH 3. Fractions were collected auto-
matically and optic densities were read in a Nikon 860 spectro-
photometer at 280 nm. Fractions were then extensively dialyzed
against phosphate buffered solution at pH 7.2 and concentrated
with Aquacide hA (Calciobiochem, Behring, La Jolla, CA, USA).
Two peaks were obtained and analyzed by immunofixation for the
presence of IgA, IgG, 1gM, kappa and lambda light chains using
monospecific antibodies.
Potential predictors for outcome measured at the time of
diagnosis which was concomitant with renal biopsy, included
clinical variables (sex, age, purpura, fever, arthralgias, hepato-
splenomegaly, neurological involvement, hypertension defined as
resting diastolic pressure above 95 mm Hg for more than 2
consecutive measurements), laboratoty variables [ciyocrit (1 10%,
2> 11%); serum creatinine (1  1.5 mgldl, 2> 1.6 mg/dl); serum C3
(1 54 mgfdl, 2> 55 mg/dl) and C4 level (1 20 mg/dl, 2> 21
mg/dl); serum IgA (1  90 mg/dl, 2> 91 420 mg/dl, 3 > 421
mg/dl), IgG (1 800 mg/dl, 2> 801  1800 mg/dl, 3> 1800 mg/dl),
1gM (1 60 mg/dl, 2 > 61  250 mg/dl, 3 > 251 mg/dl)
concentrations; platelets counted as more or less than 100,000/mm3;
urinary protein excretion: 1 = absent, 2 lower than 3.5 g/day, 3 >
than 3.5 g/day; hematuria: 1 = absent, 2 = 2+, 3 = 3+; ALT and
AST lower (= 1) or higher (= 2) than 40 UI/liter] and histological
variables.
Because the nature of the study was retrospective, treatment
regimens have varied largely. For statistical purposes, patients
could be divided in four subgroups: 21 patients never received
either steroid or cytotoxic agents, 21 patients were given steroids,
12 patients were given cytotoxic drugs alone; 61 patients were
treated by a combination of steroids and cytotoxic agents. More-
Table 1. Clinical features
During the
Signs or symptoms At diagnosis follow-up
N (%)
Purpura 73 (70) 98 (94)
Hepatomegaly 51(49) 95 (91)
Arthralgias 48 (46) 85 (81)
Fever 20 (19) 63 (60)
Splenomegaly 38 (36) 60 (57)
Neuropathy 31(22) 40 (38)
Abdominal pain 8 (8) 28 (27)
over, methylprednisolone pulses (51 patients) and plasmapheresis
(70 patients) were used in several occasions for renal or extrarenal
flare-ups.
Statistical analysis
Statistical analysis has been performed combining the two end
points: patient's death and chronic renal failure. The follow-up
was stopped at 120 months owing to the scanty number of patients
remaining at risk beyond this period, and since one cannot
exclude that the final event was not correlated with the underlying
disease over this period. The prognostic relevance of the baseline
variables on the combined events was analyzed estimating the
cumulative probability according to the Kaplan and Meier prod-
uct limit method [11]. Between groups, comparisons of continu-
ous variables were carried out by means of generalized Wilcoxon
test. Multivariate statistical analysis was performed according to
Cox's proportional hazards model using a backward procedure.
Assumptions of Cox's model were checked by graphic method and
by stratified analysis [12].
Results
The mean age of 105 patients at presentation was 52.7 10.65
years, median 52, range 21 to 75. There was a slight prevalence of
women (62/43). The median follow-up after diagnosis was 72
months ranging from ito 283 months. The median total follow-up
from the first signs and symptoms was 131 months (3 to 584).
The distribution of extrarenal signs and symptoms of EMC at
diagnosis and during the course of illness are shown in Table 1.
Purpura was the most common symptom both at the time of
diagnosis and during the follow-up. Only five patients never
developed purpura, although their follow-ups were comparable to
that of other patients. Thirty-four out of 105 patients were
examined for anti-HCV antibodies. Anti-HCV antibodies were
detected in 29 of the 34 (85%) and in the 80% of purified
cryoprecipitate fractions.
The median interval between the first symptoms of EMC and
renal involvement was 48 months (range 0 to 492). The onset of
renal disease was concomitant to that of extrarenal manifestations
of EMC in 14 patients. Proteinuria greater than 0.5 g per day and
hematuria were the most common features of renal disease at
diagnosis in 58 patients (55%). Nephritic or nephrotic syndrome
was present in 26 and 21 patients, respectively (25% and 20%).
Eighty-six patients were hypertensive (82%). Fourty-eight pa-
tients had elevated plasma creatinine at the time of renal biopsy
(47%).
Renal biopsy showed a pattern of membranoproliferative gb-
merulonephritis in 80% of patients, diffuse mesangial proliferative




























changes in 18% and focal mesangial proliferative glomerulone-
phritis in 2%. Crescents were observed in 11.4% of patients but
involved only a small number of glomeruli. Intraluminal thrombi
were the most characteristic histological feature in 26 biopsies.
Vasculitis with fibrinoid necrosis and/or proliferative changes of
arterial wall was observed in 34 specimens.
Immunofluorescent results are reported in Table 2. 1gM was
found in 98% of biopsies, IgG in 82%, IgA in 38%, C3 in 84%,
while Clq and C4 antigens were detected with less frequency and
a minor intensity (38% and 17%, respectively). Electron micros-
copy performed in 28 patients showed a picture of membrano-
proliferative glomerulonephritis in 25 and a mesangial prolifera-
tive in 3. Extensive osmiophilic deposits were present in all cases
mainly in subendothelial position, while intraluminal thrombi,
extracellular protein deposits occluding glomerular loops were
found in about 70% of cases. The extent of hyaline thrombi was
variable. Both subendothelial deposits and intraluminal thrombi
had the unique crystalloid structure consisting of 100 to 1000 nm
cylinders on longitudinal sections. On cross sections they ap-
peared as annular bodies with a diameter of 62 to 63 nm, made up
of a light center, a dense ring and a lighter peripheral coat. In the
capillary lumina a variable number of monocytes was found in all
specimens. The electron microscopy findings could not be utilized
for statistical purpose because they were available in a minority of
patients.
The cumulative 10-year probability of being alive without renal
failure after diagnosis was 0.49 (95% CI 0.60 to 0.38; Fig. 1). As
mentioned in the Methods section, for stastistical purposes only
the events occurring within 10 years from the diagnosis of EMC
have been taken into account; several patients died or developed
chronic renal failure after that interval (Table 3). During the
follow-up 42 patients died mostly of cardiovascular diseases, liver
failure or infections (Table 4), and 15 progressed to chronic renal
failure. In 7 patients death occurred during an exacerbation of
renal and extrarenal manifestation of EMC disease. Four patients
suffered from cancer: larynx carcinoma, lung carcinoma, hepato-
carcinoma and multiple myeloma, respectively, after a median
time of 70 months from the diagnosis of cryoglobulinemia (range
7 to 104). In all 4 patients death was strictly correlated with
neoplasia. Fourty-six patients were alive after a median follow-up
of 120 months. Fourteen patients were lost to follow-up after a
median time of 23.5 months (12 to 110).
Fifteen out of 105 patients had a complete and prolonged
remission of renal symptoms, whereas systemic symptoms per-
sisted. The remission occurred after a median period of 84 months
(range 2 to 156 months) since diagnosis and lasted for a median
period of 24 months (7 to 143 months). In two patients clinical
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detectable, complement levels normalized and rheumatoid factor
became negative 91 and 168 months after the onset of disease. In
one patient remission occurred after the start of regular dialysis,
in the other one signs and symptoms reversed after the patient
became HIV positive.
At univariate analysis, among the 17 clinical and laboratory
variables examined, age older than 50 years, presence of purpura,
presence of splenomegaly, low serum levels of IgG and C3, high
levels of circulating ciyoglobulins, and evidence of more severe
renal disease were significantly associated with death or chronic
renal failure (Table 5). The most significant prognostic factor was
a plasma creatinine higher than 1.5 mg/dl (Fig. 2). The fact that
hypertension was not associated with the end-points was somehow
unexpected and prompted us to furtherly evaluate this aspect. We
therefore stratified patients according to the presence or absence
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Fig. 1. Cumulative probability of survival.
Table 3. Patient outcome
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Table 5. Clinical, therapeutic and histologic predictors of death or




Age >50 years 4.98 0.026 1
Purpura 6.06 0.0138
Splenomegaly 10.75 0.0010
Plasma creatinine >1.5 mg/dl 19.67 0.0000
IgG plasma level <800 mgI dl 8.25 0.0041
C3 plasma level <54 mg/dl 15.13 0.0001
Cryocrit >10% 10.07 0.0015
Plasmapheresis 4.14 0.0418
Interstitial fibrosis 6.10 0.0135
100
0 1 3 6 12 24 36 48 60 72 84 96 108 120
Time, months after diagnosis
Fig. 2. Cumulative probability of death or chronic renal failure for the
classes by plasma creatinine at diagnosis. P = 0,000.
of hypertension and to the response to antihypertensive treat-
ment. Patients were divided into three groups: (a) non-hyperten-
sive patients (19); (b) patients with a moderate hypertension (75),
defined by the use of less than three antihypertensive drugs in
order to keep diastolic blood pressure below 100 mm Hg; (c)
patients with a refractoty hypertension [111, whose diastolic blood
pressure was higher than 100 mm Hg in spite of the use of three
or more antihypertensive drugs. The percentage of final events in
group a was 31.6%, in group b was 42.7%, and in group c was
63.6%. Although there was a trend towards a worse prognosis in
severely hypertensive patients (group c), it did not reach statistical
significance (P = 0.2312). The type of cryoglobulins was not
included in the univariate analysis since it was not tested in 18
patients. Most of the remaining patients had type II cryoglobulins.
Chi-square analysis did not show any difference between type II
and type III (data not shown).
No firm indication about therapy could be drawn from this
study. Patients were not prospectively assigned to one of the
above-mentioned therapeutical schedules, but the decision of
what and when therapy had to be initiated was taken by the doctor
in charge of the patient. We found a correlation between plasma-
pheresis and the combined end-points (P < 0.04). However, it is
likely that this correlation simply reflects our attitude to use
plasmapheresis when the disease activity was quite severe or
nonresponding to other treatment.






Age >50 years 2.46 1.21
Vascular purpura 2.22 1.00
Splenomegaly 2.09 1.10
Cryocrit levels >10% 2.33 1.21
C3 plasma levels <54 mg/dl 2.36 1.24
Serum creatinine 1.5 mgldl 2.15 1.11
Among the histological variables, only interstitial fibrosis was
associated with the combined end-points. Neither the activity (P
= 0.5252) nor the chronicity indices (P = 0.4464) predicted the
final outcome. The apparent discrepancy between the significance
of interstitial fibrosis and the nonsignificance of chronicity index
may be explained by the fact that interstial fibrosis contributed for
only one fourth to the total chronicity score.
At multivariate analysis older age, vascular purpura, spleno-
megaly, high cryocrit levels, low C3 plasma levels, and high plasma
creatinine at the time of biopsy were identified as independent
prognostic indices significantly correlated with death or renal
failure (Table 6).
Discussion
In this series the three major clinical features of EMC, namely
purpura, arthralgias, hepatomegaly occurred very frequently dur-
ing the course of the disease similarly to what reported in previous
studies [1—4]. Of note, however, five patients never showed
purpuric lesions, although they had a follow-up time comparable
with that of the other patients. In this series 85% of tested patients
had positive HCV antibodies. These data are in agreement with
previous studies showing that 50% to 100% of patients with EMC
were HCV positive [5, 13—15]. Abnormal liver function tests were
detected in 25% of patients during the follow-up, similarly to the
27% reported by Cordonnier et al [16] and the 24% reported by
Invernizzi et a! [4]. Conversely Gorevic et al [8] reported an
increase of liver enzymes in 70% and Bombardieri et a! [17] in
84% of their patients with EMC. It is difficult to explain these
discrepancies, but it is possible that patients in the series of
Gorevic and Bombardieri had more severe EMC. Peripheral
neurophathy was observed in 22% of our patients. In previous
smaller series this complication was found to be rare [1, 181, but
when electromyography was routinely made an abnormal periph-
eral nerve conducibility was found in 68% to 82% of patients with
EMC [19, 20]. In some reports pulmonary symptoms were ob-
served only occasionally [17, 21] and death due to acute respira-
tory distress was a rare event [16, 22, 23]. However, when
pulmonary function was routinely investigated [24], functional
abnormalities referred to the immunological aggression to lung
interstitium were observed in 61% of patients. Abdominal colicky
pain affected only few patients in this series. It is generally caused
by intestinal vasculitis initiated by the deposition of circulating
cryoglobulins, even if the occurrence of intestinal infarct is
confined to isolated cases [25]. Lymphoadenopathy, SjOgren's
syndrome, thrombocytopenia, central nervous system involvement
and Raynaud's phenomenon were rarely observed in our experi-
ence as well as in other series [26, 27].
All our patients had some signs of kidney disease but this datum
is biased by the fact that all patients were hospitalized in three
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renal units. Renal involvement was reported in 2 to 50% of
patients in previous studies [2, 3, 9, 26]. It is possible that besides
differences in patients selection, ethnic and racial factors as well as
different criteria for diagnosis can account for these discrepancies.
The present study that collected the largest number of patients
with EMC nephritis, confirms a poor prognosis for these patients.
Among 105 patients followed for a median period of 131 months
from the onset of the disease, 42 died and 15 developed ESRD.
The other 15 patients who were in long-lasting remission of renal
manifestation had recurrent episodes of systemic symptoms and
persistence of laboratory parameters related to circulating cryo-
globulins. The remaining patients showed an unremitting course,
excluding two patients who underwent a complete disappearance
of both clinical and laboratory features respectively after the
discovery of HIV infection and after the beginning of dialytic
treatment. Although our patients with EMC nephritis had a bad
prognosis, the mortality rate was lower than that reported in other
series. Death was reported in 18 of 22 patients by Gorevic et al [8],
in 12 of 15 by Cordonnier et al [16], in 8 of 12 patients by Frankel
et al [28] and in 12 of 21 patients by Invernizzi et al [261
notwithstanding, the follow-ups were comparable with that of our
patients. In our patients death was mainly related to cardiovascu-
lar disease, while the number of patients who developed chronic
renal failure was small (15 to 105). These results would indicate
that most patients with EMC nephritis die before renal failure
develops. It is likely that hypertension and vasculitis contributed
to the high rate of cardiovascular disease. On the other hand, the
poor prognosis observed in older patients suggests that factors not
related to the disease per se can also influence the outcome of
these patients.
Multivariate analysis showed that among the clinical variables
tested, older age, purpura, splenomegaly, elevated plasma creat-
mine at presentation, high serum cryocrit and low C3 serum levels
were independent predictors for death or for development of
renal failure.
To our surprise, hypertension was not associated with a poor
outcome. To better evaluate the role of hypertension, we stratified
patients into three groups. There was a trend to a bad prognosis
for patients with poorly controlled hypertension in comparison
with patients with controlled hypertension or spontaneously nor-
mal blood pressure. This difference was not significant, possibly
because of the small number of patients at risk.
Therapy did not influence the final oucome. This may be due
either to the low effectiveness of the treatments or to the fact that
corticosteroids, immunosuppressive drugs and/or plasmapheresis
were given only in the most severe cases. The use of steroids
and/or cytotoxic agents in EMC is still controversial, especially in
the long-term. Considering whether or not a patient has to be
given a therapy, one should bear in mind that the disease usually
takes a long time to evolve into renal failure and it is punctuated
by flare-ups. Therefore, we feel that an aggressive treatment
should be reserved only for the acute flare-ups [29, 30]. The
current therapeutical approach will be probably modified after the
discovery that hepatitis C virus infection represents a pathoge-
netic factor in EMC. Agents capable to inhibit viral replication
such as interferon alpha could play a major role in the treatment
of the disease at least when renal disease is not too advanced [31,
32].
None of the histological variables had an independent prognos-
tic significance even when evaluated as activity or chronicity index.
This might be expected since it is unlikely that a renal biopsy made
at some time could predict the long-term outcome of a disease
characterized by recurrent flares of renal and extrarenal symp-
toms [32]. On the other hand, renal biopsy is important not only
to differentiate EMC from other fibrillar diseases by electron
microscopy, but also in making the therapeutic decision as it
distinguishes active disease from irreversible chronic lesions in
patients with renal failure.
The possibility that EMC can evolve into an hematological
malignancy has been described [8, 91. In this study four patients
developed malignancies, among which two were of hematological
origin. Theoretically, these cases could be accounted for either by
the oncogenic effect of a prolonged immunosuppression or by the
abnormal proliferation of a B cell clone producing 1gM rheuma-
toid factor with eventual malignant transformation.
In summary, several factors may influence the outcome of
patients with EMC nephritis. Markers of disease activity and an
impaired renal function with or without severe proteinuria can
herald a bad prognosis. In these patients death often precedes
end-stage renal failure so that only a minority of patients has to be
submitted eventually to regular dialysis.
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